Prevention of coronary heart disease

BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7436.405-b (Published 12 February 2004) Cite this as: BMJ 2004;328:405

Data in table 2 could be shown more explicitly for better understanding

  1. Andrea Messori, coordinator (andreamessori{at}interfree.it),
  2. Benedetta Santarlasci, researcher
  1. Laboratorio SIFO di Farmacoeconomia, Careggi University Hospital, 50134 Florence, Italy

    EDITOR—The cost effectiveness study published by Marshall is difficult to understand in its technical details not only by average readers but also people with some skill in pharmacoeconomics.1

    We think that the part of this study that presents the data of the average cost effectiveness (table 1 of the article) is useless because the practical implications of this study, along with the assessment of the pharmacoeconomic profile of the various drugs, rely exclusively on the findings of the incremental cost effectiveness analysis (the data presented in table 2).

    Table 2 is not adequately explained by the author. For this reason, we propose a more detailed layout, in which much more information is presented and the labelling of each row is made more explicit (see bmj.com).


    • Embedded ImageSee table on bmj.com

    • Competing interests None declared.


    View Abstract

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial